Read more

February 05, 2020
1 min read
Save

Top stories in endocrinology: FDA OKs first triple combination pill for diabetes, apps help people with diabetes lose weight

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA approved Trijardy XR, the first oral therapy to combine three type 2 diabetes medications into one pill. It was the week’s top story in endocrinology.

Another top story was about a study that found people with type 2 diabetes may lose weight more effectively if they used a weight-loss mobile app.

FDA approves first triple combination pill for type 2 diabetes

The FDA approved the first oral therapy to combine three type 2 diabetes medications into one pill: the SGLT2 inhibitor empagliflozin, the DPP-IV inhibitor linagliptin and metformin hydrochloride extended release, according to a press release from Boehringer Ingelheim and Eli Lilly and Co. Read more.

Mobile apps may facilitate weight loss among adults with type 2 diabetes

Phone apps 
Another top story was about a study that found people with type 2 diabetes may lose weight more effectively if they used a weight-loss mobile app.
Source: Shutterstock

Adults with type 2 diabetes may lose weight more effectively by including a weight-loss mobile app as part of their strategy, according to findings from a meta-analysis published in Obesity. Read more.

New genetic discoveries help predict risk for type 1, type 2 diabetes

Researchers continue to discover more each year about the genetic risk factors for type 1 and type 2 diabetes and how those risk factors interact with the environment. Scientists have linked several genetic mutations to diabetes risk, though not everyone with a genetic mutation will go on to develop the disease. Read more.

Dual-hormone artificial pancreas ‘next logical treatment’ for type 1 diabetes

Adults with type 1 diabetes may be able to maintain their glucose levels in target range longer, particularly during the day, by using an artificial pancreas with rapid-acting insulin and pramlintide, according to findings published in Diabetes Care. Read more.

High childhood HbA1c increases premature death risk in type 1 diabetes

Young adults with type 1 diabetes were nearly three times more likely to die before age 30 years if they had poor metabolic control during childhood, according to findings from a Swedish registry-based study. Read more.